HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 07-27-2009, 02:40 PM   #1
Hopeful
Senior Member
 
Join Date: Aug 2006
Posts: 3,380
Advances Elusive in the Drive to Cure Cancer

http://www.nytimes.com/2009/04/24/he...agewanted=1&hp

Related article: http://www.nytimes.com/2009/04/24/he...tics%22&st=nyt

Hopeful

Last edited by Hopeful; 07-27-2009 at 07:33 PM..
Hopeful is offline   Reply With Quote
Old 07-27-2009, 07:01 PM   #2
Laurel
Senior Member
 
Laurel's Avatar
 
Join Date: May 2008
Location: Hershey, PA. Live The Sweet Life!
Posts: 2,005
depressing......
__________________

Smile On!
Laurel


Dx'd w/multifocal DCIS/IDS 3/08
7mm invasive component
Partial mast. 5/08
Stage 1b, ER 80%, PR 90%, HER-2 6.9 on FISH
0/5 nodes
4 AC, 4 TH finished 9/08
Herceptin every 3 weeks. Finished 7/09
Tamoxifen 10/08. Switched to Femara 8/09
Bilat SPM w/reconstruction 10/08
Clinical Trial w/Clondronate 12/08
Stopped Clondronate--too hard on my gizzard!
Switched back to Tamoxifen due to tendon pain from Femara

15 Years NED
I think I just might hang around awhile....

Laurel is offline   Reply With Quote
Old 07-27-2009, 07:37 PM   #3
Hopeful
Senior Member
 
Join Date: Aug 2006
Posts: 3,380
Sorry, Laurel, my links were not right. All that posted was the related article. I have corrected it so that the lead article is there. Here is what I thought was most important about it:

"There also are unnecessary roadblocks. Research lurches from fad to fad — cancer viruses, immunology, genomics. Advocacy groups have lobbied and directed research in ways that have not always advanced science. And for all the money poured into cancer research, there has never been enough for innovative studies, the kind that can fundamentally change the way scientists understand cancer or doctors treat it. Such studies are risky, less likely to work than ones that are more incremental. The result is that, with limited money, innovative projects often lose out to more reliably successful projects that aim to tweak treatments, perhaps extending life by only weeks.
“Actually, that is the biggest threat,” said Dr. Robert C. Young, chancellor of the Fox Chase Cancer Center in Philadelphia. “Every organization says, ‘Oh, we want to fund high-risk research.’ And I think they mean it. But as a matter of fact, they don’t do it.”


Hopeful
Hopeful is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 08:57 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter